|
|
||||||||
Department of Microbiology and Immunology, University of Miami School of Medicine, Miami, FL 33136
Although CD30 has long been recognized as an important marker on many lymphomas of diverse origin and as activation molecule on B cells and T cells, its primary function has remained obscure. We now report that CD30 signals may serve to inhibit effector cell activity by integrating gene expression changes of several pathways important for cytotoxic NK and T cell effector function. In the large granular lymphoma line YT, CD30 signals down-regulate the expression of cytotoxic effector molecules, Fas ligand, perforin, granzyme B, and abrogate cytotoxicity. c-myc, a regulator of proliferation and an upstream regulator of Fas ligand expression, is completely suppressed by CD30. Furthermore, CD30 signals strongly induce CCR7, suggesting a role for CD30 signals in the homing of lymphocytes to lymph nodes. The up-regulation of Fas, death receptor 3, and TNF-related apoptosis-inducing ligand by CD30 indicates an increase in susceptibility to apoptotic signals whereas up-regulation of TNFR-associated factor 1 and cellular inhibitor of apoptosis 2 protect cells from certain types of apoptosis. Using gene microarrays, 750 gene products were induced and 90 gene products were suppressed >2-fold by CD30 signals. Signals emanating from CD30 use both TNFR-associated factor 2-dependent and -independent pathways. The integration of CD30 signals in a lymphoma line suggests that CD30 can down-modulate lymphocyte effector function and proliferation while directing the cells to lymph nodes and increasing their susceptibility to certain apoptotic signals. These studies may provide a molecular mechanism for the recently observed CD30-mediated suppression of CTL activity in vivo in a diabetes model.
This article has been cited by other articles:
![]() |
E. Y. Chan, W.-J. Qian, D. L. Diamond, T. Liu, M. A. Gritsenko, M. E. Monroe, D. G. Camp II, R. D. Smith, and M. G. Katze Quantitative Analysis of Human Immunodeficiency Virus Type 1-Infected CD4+ Cell Proteome: Dysregulated Cell Cycle Progression and Nuclear Transport Coincide with Robust Virus Production J. Virol., July 15, 2007; 81(14): 7571 - 7583. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Zeiser, V. H. Nguyen, J.-Z. Hou, A. Beilhack, E. Zambricki, M. Buess, C. H. Contag, and R. S. Negrin Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease Blood, March 1, 2007; 109(5): 2225 - 2233. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Nishimura, T. Yajima, H. Muta, E. R. Podack, K. Tani, and Y. Yoshikai A Novel Role of CD30/CD30 Ligand Signaling in the Generation of Long-Lived Memory CD8+ T Cells J. Immunol., October 1, 2005; 175(7): 4627 - 4634. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. R. Blazar, R. B. Levy, T. W. Mak, A. Panoskaltsis-Mortari, H. Muta, M. Jones, M. Roskos, J. S. Serody, H. Yagita, E. R. Podack, et al. CD30/CD30 Ligand (CD153) Interaction Regulates CD4+ T Cell-Mediated Graft-versus-Host Disease J. Immunol., September 1, 2004; 173(5): 2933 - 2941. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. I. Berro, G. A. Perry, and D. K. Agrawal Increased Expression and Activation of CD30 Induce Apoptosis in Human Blood Eosinophils J. Immunol., August 1, 2004; 173(3): 2174 - 2183. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-C. Su, H.-H. Chiu, C.-C. Chang, J.-C. Chen, and S.-M. Hsu CD30 Is Involved in Inhibition of T-Cell Proliferation by Hodgkin's Reed-Sternberg Cells1 Cancer Res., March 15, 2004; 64(6): 2148 - 2152. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Owen, V. Iragavarapu-Charyulu, Z. Gunja-Smith, L. M. Herbert, J. F. Grosso, and D. M. Lopez Up-Regulation of Matrix Metalloproteinase-9 in T Lymphocytes of Mammary Tumor Bearers: Role of Vascular Endothelial Growth Factor J. Immunol., October 15, 2003; 171(8): 4340 - 4351. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Phillips, J. Ni, and J. S. Hunt Cell-specific expression of B lymphocyte (APRIL, BLyS)- and Th2 (CD30L/CD153)-promoting tumor necrosis factor superfamily ligands in human placentas J. Leukoc. Biol., July 1, 2003; 74(1): 81 - 87. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Saraiva, P. Smith, P. G. Fallon, and A. Alcami Inhibition of Type 1 Cytokine-mediated Inflammation by a Soluble CD30 Homologue Encoded by Ectromelia (Mousepox) Virus J. Exp. Med., September 16, 2002; 196(6): 829 - 839. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. E. Hopken, H.-D. Foss, D. Meyer, M. Hinz, K. Leder, H. Stein, and M. Lipp Up-regulation of the chemokine receptor CCR7 in classical but not in lymphocyte-predominant Hodgkin disease correlates with distinct dissemination of neoplastic cells in lymphoid organs Blood, February 15, 2002; 99(4): 1109 - 1116. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Vinante, A. Rigo, M. T. Scupoli, and G. Pizzolo CD30 triggering by agonistic antibodies regulates CXCR4 expression and CXCL12 chemotactic activity in the cell line L540 Blood, January 1, 2002; 99(1): 52 - 60. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Joussen, S. Huang, V. Poulaki, K. Camphausen, W.-D. Beecken, B. Kirchhof, and A. P. Adamis In Vivo Retinal Gene Expression in Early Diabetes Invest. Ophthalmol. Vis. Sci., November 1, 2001; 42(12): 3047 - 3057. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |